lisdexamfetamine / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 42 Diseases   13 Trials   13 Trials   1240 News 
20 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
lisdexamfetamine / Generic mfg.
ACTRN12618000623291: Neural mechanisms of lisdexamfetamine in binge eating disorder.

Recruiting
4
62
 
University of Sydney, Shire International GmbH
Binge-Eating Disorder
 
 
ACTRN12621000045819: An open-label trial of oral lisdexamfetamine for the treatment of acute methamphetamine withdrawal

Recruiting
4
15
 
St Vincent's Hospital Sydney, The National Centre for Clinical Research on Emerging Drugs
Acute methamphetamine withdrawal
 
 
NCT01413165: Phase 4, Open Label, Multicentre, 2 Year Safety Study of Lisdexamfetamine Dimesylate in Children/Adolescents With ADHD

Not yet recruiting
4
12
Europe
Lisdexamfetamine dimesylate, SPD 489
Maastricht University Medical Center, Shire Development LLC
Attention Deficit Disorder With Hyperactivity
08/13
12/13
NCT03337646: Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism

Completed
4
48
Canada
Lisdexamfetamine Dimesylate, Vyvanse
JPM van Stralen Medicine Professional, Shire
Attention Deficit Hyperactivity Disorder, Autism Spectrum Disorder
03/23
03/23
NCT03420339: Stimulant Effects on Disruptive Behavior

Recruiting
4
10
US
Stimulant, Adderall, Concerta, Aptensio, Daytrana, Metadate, Quillivant, Ritalin, Focalin, Vyvanse
Matthew J O'Brien, PhD, BCBA-D
Attention Deficit Hyperactivity Disorder, Problem Behavior
01/25
01/25
ACTRN12617000657325: Lisdexamfetamine for the treatment of methamphetamine addiction

Completed
3
180
 
University of New South Wales , National Health and Medical Research Council, Curran Foundation
Addiction, Methamphetamine dependence
 
 
NCT03924193: Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Acute Treatment

Completed
3
141
US
Lisdexamfetamine Dimesylate, Cognitive-Behavioral Therapy, Combination LDX and Cognitive-Behavioral Therapy
Yale University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Binge-Eating Disorder, Obesity
09/23
09/23
NCT03926052: Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Maintenance Treatment

Active, not recruiting
3
80
US
Lisdexamfetamine Dimesylate, Placebo
Yale University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Binge-Eating Disorder, Obesity
07/24
07/24
NCT04599504: Pharmacological and Behavioral Treatment After Bariatric Surgery: Medication Change for Non-Responders (Stage 2b)

Enrolling by invitation
2/3
60
US
Lisdexamfetamine Dimesylate (Medication), Vyvanse, Placebo
Yale University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Loss-of-control Eating, Obesity/Overweight
05/27
05/27
2017-001490-16: Treatment of Bulimia Nervosa, with and without simultaneous probable ADHD, with the stimulant medicine Lisdexamphetamin . Behandling av Bulimia Nervosa, med och utan samtidig sannolik ADHD, med den psykostimulerande medicinen Lisdexamfetamin.

Ongoing
2
50
Europe
Capsule, hard, Elvanse vuxen
Stockholms läns landsting, Stiftelsen Söderström-Königska sjukhemmet, Petrus och Augusta Hedlunds stiftelse
Bulimia Nervosa with and without simultaneous Attention Deficit Hyperactivity Disorder. Bulimia Nervosa med och utan samtidig Attention Deficit Hyperactivity Disorder., Bulimia Nervosa with and without simultaneous ADHD Bulimia Nervosa med och utan samtidig ADHD, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2022-001906-24: LAMAinDiab - comparison of 2 pharmacological therapies (lisdexamphetamine vs methylphenidate) for pediatric patients with ADHD and type 1 diabetes - a randomized crossover clinical trial   LAMAinDiab – porównanie 2 terapii farmakologicznych (lisdeksamfetamina vs metylfenidat) dla pacjentów pediatrycznych z zespołem ADHD i cukrzycą typu 1 - randomizowane krzyżowe badanie kliniczne .

Not yet recruiting
2
150
Europe
Elvanse, Concerta, Capsule, hard, Prolonged-release tablet
Medical University in Lodz, Agencja Badań Medycznych
Patients with ADHD and type I diabetes. Pacjenci z ADHD i Cukrzycą typu I., Patients with ADHD and type I diabetes. Pacjenci z ADHD i Cukrzycą typu I., Not possible to specify
 
 
NCT05854667: Clinical Trial of High Dose Lisdexamfetamine and Contingency Management in MA Users

Recruiting
2
440
Canada
Treatment as Usual plus Placebo, Contingency Management, Treatment as Usual plus Placebo plus Contingency Management, Treatment as Usual plus lisdexamfetamine (LDX-01), Treatment as Usual plus lisdexamfetamine (LDX-01) plus Contingency Management
Centre hospitalier de l'Université de Montréal (CHUM), Canadian Institutes of Health Research (CIHR)
Methamphetamine Abuse, Methamphetamine-dependence, Addiction, Substance, Addiction
11/25
11/25
LAMAinDiab, NCT05957055: Lisdexamphetamine vs Methylphenidate for Pediatric Patients With ADHD and Type 1 Diabetes

Not yet recruiting
2
150
NA
parental training in behavior management, PT training, Lisdexamfetamine, LDX, Methylphenidate, MPH
Medical University of Lodz, Medical University of Silesia, Medical University of Gdansk, Institute of Medical Sciences of the University of Opole, Pediatric Center of the Central Clinical Hospital of the Medical University of Lodz
Attention Deficit Disorder With Hyperactivity, Diabetes Mellitus, Type 1
12/27
12/27
NCT05416125: Vyvanse in Children Aged 6 to 12 Years

Recruiting
1
40
US
Lisdexamfetamine Dimesylate, Lifestyle therapy
University of Minnesota
Obesity, Childhood
11/28
11/29
ADAPT, NCT02136147: ADHD Medication and Predictors of Treatment Outcome

Completed
N/A
632
Europe
methylphenidate medication, N06BA04, Concerta, Ritalin, Equasym, Medikinet, atomoxetine medication, N06BA09, Strattera, lisdexamphetamine medication, N06BA12, Elvanse, guanfacine medication, C02AC02, Intuniv
Karolinska Institutet
Attention Deficit Disorder With Hyperactivity (ADHD)
07/21
06/22
NCT04727476: The Use of Lisdexamfetamine for Children Aged 7-13 With Attention Deficit Disorders

Active, not recruiting
N/A
413
Europe
Lisdexamfetamine
Aarhus University Hospital, Takeda
Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, Hyperkinetic Disorder
08/21
05/22
IDEAL, NCT04946461: The Day-time Response Variation of (Lis)Dexamphetamine

Completed
N/A
16
Europe
Dexamfetamine Sulfate 5 Mg Oral Tablet, Tentin, Lisdexamfetamine Dimesylate, Elvanse, blood samples, vena puncture
Amsterdam UMC, location VUmc, ADHDcentraal
Adhd
12/21
06/22
NCT05551689: FOCUS ADHD Mobile Health App for Adult ADHD Patients

Completed
N/A
73
RoW
Psychostimulant, Methilphenidate, Lisdexamfetamine, FOCUS ADHD App, mhealth app
Hospital de Clinicas de Porto Alegre, University of Sao Paulo
ADHD
09/22
03/23
AGUALIS, NCT03333668: Experimental fMRI Study of Guanfacine and Lisdexamfetamine in ADHD Adolescents

Active, not recruiting
N/A
20
Europe
Lisdexamfetamine dimesylate, Vyvanse (Shire Pharmaceuticals Ltd.), Guanfacine Extended Release Oral Tablet, Intuniv (Shire Pharmaceuticals Ltd.), Placebo
King's College London, Shire
ADHD
12/22
03/25
NCT03497169: Bariatric Surgery and Pharmacokinetics of Lisdexamphetamine

Recruiting
N/A
12
Europe
Lisdexamfetamine Dimesylate, Lisdexamfetamine, Vyvanse, Elvanse
Norwegian University of Science and Technology, St. Olavs Hospital, Volvat Medisinsk Senter Stokkan, Namsos Hospital, Alesund Hospital
Obesity, Morbid
10/26
10/26

Download Options